Re: Ola Bratt, Erik Holmberg, Ove Andrén, et al. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). Eur Urol 2019;76:461–6

Publication date: Available online 25 February 2020Source: European UrologyAuthor(s): Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, Alberto Briganti
Source: European Urology - Category: Urology & Nephrology Source Type: research

Related Links:

Publication date: Available online 27 March 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Srinivasa R. Rao, Nasullah K. Alham, Elysia Upton, Stacey McIntyre, Richard J. Bryant, Lucia Cerundolo, Emma Bowes, Stephanie Jones, Molly Browne, Ian Mills, Alastair Lamb, Ian Tomlinson, David Wedge, Lisa Browning, Korsuk Sirinukunwattana, Claire Palles, Freddie C. Hamdy, Jens Rittscher, Clare Verrill
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Publication date: Available online 27 March 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Haisong Tan, Nan Hou, Yanlei Liu, Bin Liu, Wen Cao, Dachao Zheng, Wenzhi Li, Yushan Liu, Bin Xu, Zhong Wang, Daxiang Cui
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
AbstractMultiparametric MRI (mpMRI) of the prostate has been firmly established as a tool in the diagnosis, management, and treatment of prostate cancer. The growth in this field over the past decade has led to increased acceptance and demand for multiparametric prostate MRI across the world. However, with the rising demand for prostate mpMRI, it will become increasingly necessary to train a generation of dedicated prostate imagers to yield a high-quality product.
Source: Abdominal Imaging - Category: Radiology Source Type: research
Conclusions: The recently developed MRI ADC map-based radiomics model was validated in terms of its predictive accuracy of BCR and bRFS after prostatectomy in an external cohort.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 27 March 2020Source: Academic RadiologyAuthor(s): Harrison Kim, John V. Thomas, Jeffrey W. Nix, Jennifer B. Gordetsky, Yufeng Li, Soroush Rais-Bahrami
Source: Academic Radiology - Category: Radiology Source Type: research
Stereotactic ablative radiotherapy (SABR) of oligometastatic disease was superior to observation in men with hormone-sensitive prostate cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Conclusion: Our outcomes support equivalent efficacy and similar risk of adverse effects between apalutamide, enzalutamide, and darolutamide, supporting the use of these antiandrogen agents in high-risk of progression nmCRPC.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
A form of highly focused, intense radiation therapy called stereotactic ablative...Read more on AuntMinnie.comRelated Reading: PSMA-PET/CT again shows prowess for prostate cancer MRI-targeted biopsy optimizes prostate cancer detection ASTRO: SABR generates immune response to prostate cancer SABR plus surgery is effective for treating lung cancer ASTRO: SABR is effective for oligometastatic cancers
Source: Headlines - Category: Radiology Source Type: news
Prostate-specific membrane antigen PET/CT was found to be a suitable replacement for conventional imaging in patients with prostate cancer, providing superior accuracy to the combined findings of CT and bone scanning.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
(Impact Journals LLC) Oncotarget Volume 11, Issue 12 reported outside its natural niche, the cultured prostate cancer stem cells lost their tumor-inducing capability and stem cell marker expression after approximately 8 transfers at a 1:3 split ratio.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Prostate Cancer | Study | Sweden Health | Urology & Nephrology